Apices Soluciones

• A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

  Collaborator, Phase 3, Active, not recruiting, 101 people, 8 Jan 2025

• Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors

  Collaborator, Not yet recruiting, 32 people, 18 Nov 2023

• NCT04494958

  Collaborator, Phase 1/2, Completed, 24 people, 31 Jul 2020

• NCT04483505

  Collaborator, Phase 1, Completed, 9 people, 23 Jul 2020

• NCT04348695

  Collaborator, Phase 2, Completed, 94 people, 16 Apr 2020

• NCT04282109

  Collaborator, Phase 2, Completed, 141 people, 24 Feb 2020

• Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)

  Collaborator, Phase 2, Completed, 34 people, 13 Nov 2019

• NCT03598270

  Collaborator, Phase 3, Completed, 417 people, 26 Jul 2018

• NCT03556839

  Collaborator, Phase 3, Completed, 410 people, 14 Jun 2018

• NCT03448731

  Collaborator, Phase 2, Completed, 34 people, 28 Feb 2018

• NCT02036060

  Collaborator, Phase 2, Completed, 119 people, 14 Jan 2014

• NCT01703910

  Collaborator, Phase 2, Completed, 29 people, 11 Oct 2012

Sources: clinicaltrials.gov